Executive Summary / Key Takeaways
-
NIKA Pharmaceuticals is a pre-revenue pharmaceutical company with a going concern qualification, $9 million in accumulated deficits, and negative working capital of $298K, yet commands a $398 million market cap based on speculative pipeline potential and a partially constructed Bulgarian factory.
-
The company exists through related-party financing, with CEO Dimitar Savov personally owed $205K and having personally guaranteed equipment purchases, creating dependency on a single individual's continued capital support.
-
Despite holding exclusive rights to Thymus Nuclear Glycoprotein (TNG) for HIV and the Inactivated Pepsin Fraction (IPF) platform, NIKA has made no regulatory progress since acquiring these assets in 2022, while competitors like Gilead Sciences (GILD) and Merck & Co. (MRK) generate billions from approved antivirals.
-
The Bulgarian pharmaceutical factory represents NIKA's only tangible path to revenue, but the company faces significant hurdles in capital, regulatory approvals, and competitive positioning to manufacture ITV-1.
-
Investment asymmetry is extreme: upside requires successful factory launch, regulatory approvals across multiple continents, and market penetration against entrenched giants; downside is immediate insolvency if related-party financing withdraws.
Setting the Scene: A Shell Company's Pharmaceutical Fantasy
Nika Pharmaceuticals, Inc. began life in 2000 as Centennial Growth Equities, Inc., a Colorado shell company that remained dormant for two decades until a change of control in April 2022. When Dimitar Slavchev Savov acquired majority ownership and installed himself as President, CEO, and CFO, he inherited a corporate entity with no operations, no revenue, and no liabilities beyond its corporate charter. Every asset NIKA now claims was acquired through related-party transactions and exclusive agreements signed within a five-month window in 2022, none of which have generated revenue in the three years since.
The business model involves NIKA holding exclusive 15-year rights to produce and distribute Thymus Nuclear Glycoprotein (TNG), a compound that completed Phase III trials for AIDS treatment in 1998, alongside dietary supplements Carotilen and Physiolong. Through its 80% controlling interest in Nika Europe, Ltd., the company plans to manufacture these products in a Bulgarian factory currently under construction. This positioning places NIKA in direct competition with Gilead Sciences, Merck & Co., AbbVie (ABBV), and Pfizer (PFE)—companies that generated significant combined revenue in 2025 while NIKA generated zero.
Industry structure reveals NIKA's positioning. The HIV therapeutics market alone exceeds $30 billion annually, dominated by Gilead's Biktarvy with over 50% global market share and Merck's integrase inhibitors achieving high viral suppression rates. These competitors spend billions annually on R&D, maintain global distribution networks, and hold portfolios of approved, reimbursed products. NIKA's strategy of offering "affordable immune boosters" for emerging markets faces significant hurdles: without FDA or EMA approval, without clinical data proving superiority or non-inferiority to existing therapies, and without manufacturing scale, NIKA faces difficulty accessing these markets.
Technology, Products, and Strategic Differentiation: A Pipeline of Promises
Thymus Nuclear Glycoprotein (TNG) represents NIKA's flagship asset, acquired via exclusive rights agreement in April 2022. The compound completed Phase III clinical trials in 1997-1998, yet no regulatory submissions have occurred in the three years since NIKA acquired the rights. Pharmaceutical assets do not necessarily appreciate with age—1998 trial data is dated by modern standards, and any regulatory pathway would require substantial new studies costing tens of millions of dollars. While Gilead's lenacapavir advances through Phase 3 trials as a six-month injectable, NIKA's TNG remains a historical asset rather than a competitive product.
The Inactivated Pepsin Fraction (IPF) platform, covered by several U.S. patents, has seen no disclosed development progress, regulatory filings, or partnership revenue since its acquisition in August 2022. Patent protection requires capital to develop products, conduct trials, and navigate regulatory approval—a process that often costs $100 million per drug on average. NIKA's entire operating expense budget in 2025 was $76,398.
The dietary supplement portfolio reveals the company's market position. Carotilen and Physiolong, acquired alongside TNG, are positioned as general wellness products. This exposes NIKA's actual strategy: selling unregulated supplements while maintaining pharmaceutical rights. The six additional supplements acquired from CEO Savov in August 2022—Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron—face no regulatory barriers to entry and compete in commoditized markets where branding and distribution dominate.
ITV-1 production economics illustrate the gap between projection and reality. The September 2024 production agreement with Nika Europe estimates a framework price of $580 per set with an expected profit of $1,120 per set. These numbers are theoretical without a factory, regulatory approval for ITV-1, established demand, and sales channels. Gilead generates billions annually from HIV sales at high gross margins; NIKA projects theoretical margins on a product not yet in production.
Financial Performance & Segment Dynamics: The Mathematics of Insolvency
NIKA's financial statements show corporate survival through related-party support. For the year ended December 31, 2025, the company reported zero revenue, a net loss of $76,398, and negative operating cash flow of $79,654. These losses occur despite minimal operations—the company has no sales force, no manufacturing, and no R&D programs. The slight improvement in net loss from 2024 is minor when the absolute numbers reflect a company that burns cash merely existing.
General and administrative expenses increased 50.75% to $53,026, driven by transfer agent fees and website maintenance. This shows costs rising even as the company generates zero revenue. Professional fees decreased 61.44% to $23,372, reflecting reduced audit and legal work, but this cost cutting coincides with governance challenges: the company admits its disclosure controls are ineffective due to material weaknesses, including the absence of an audit committee and lack of segregation of duties.
The balance sheet reveals dependency. As of December 31, 2025, NIKA owed $79,460 to Nika Europe LTD, $205,164 to CEO Dimitar Savov, and $34,000 to Nika Pharmaceuticals LTD. These advances are non-interest bearing and due on demand. The company's liquidity position depends on these related entities choosing not to call their loans. If support is withdrawn, NIKA faces immediate insolvency. The $9 million accumulated deficit means every dollar of assets is offset by historical losses.
Cash flow analysis shows the funding situation. Net cash used in operations decreased from $154,932 to $79,654, but this reflects reduced professional fees rather than operational progress. The company received $79,460 in loan proceeds from related parties in 2025, down from $137,419 in 2024. With negative working capital of $297,628, NIKA requires continuous capital injection to meet current obligations.
Outlook, Management Guidance, and Execution Risk: Confessions of a Going Concern
Management's guidance states that the company will continue to incur losses and negative cash flows for the foreseeable future and will need additional equity or debt financing to sustain its operations until it can achieve profitability, if ever. This is a direct admission that the current business model requires external support and that shareholders face potential dilution.
The Bulgarian factory represents the primary catalyst for potential revenue generation. Nika Europe signed a supply agreement for a vial production line in April 2024, with equipment delivery scheduled for Q4 2024 and CEO Savov personally funding the $191,534 down payment. However, the acquisition of Nika Pharmaceuticals, Ltd. that would have given NIKA 99.99% control of the factory was canceled in August 2024, returning ownership to Savov personally. This means the factory is not currently consolidated into the public entity.
The March 2026 consultancy agreement with MD Global Partners LLC to assist with capital raising suggests NIKA is seeking specialized channels for funding. CEO Savov's statement regarding expected growth once the production factory is operational is contingent on the company meeting future operational milestones.
Execution risk is significant. The company must complete factory construction, obtain regulatory approvals, establish distribution channels, and compete with established pharmaceutical giants while managing cash burn. The CFO role is held by the CEO, the board lacks independent directors, and no audit committee exists, which presents challenges for overseeing complex regulatory requirements.
Risks and Asymmetries: When Zero Revenue Meets Infinite Risk
The going concern qualification is a factual assessment by auditors citing the accumulated deficit, net losses, and negative working capital as evidence of substantial doubt regarding the company's ability to continue operations. This means financial statements are prepared under the assumption that the company may not be able to realize its assets and discharge its liabilities in the normal course of business.
Material weaknesses in internal control create risks regarding oversight. The lack of segregation of duties means the CEO handles multiple financial functions. The absence of an audit committee means there is no independent review of financial reporting. Furthermore, the company has not adopted formal insider trading policies.
Cybersecurity risk management is currently not a formalized process. Management states they have no specific processes for identifying cybersecurity threats. For a pharmaceutical company with intellectual property assets and regulatory data, the lack of a cybersecurity framework represents a potential vulnerability.
Competitive dynamics are a major hurdle. Gilead's lenacapavir, a twice-yearly HIV injection, achieved high viral suppression in trials. Merck's Keytruda dominates oncology, and AbbVie's Skyrizi and Rinvoq have shown strong market performance. Against these realities, NIKA's 1998-era TNG data and unproven supplements face a difficult competitive landscape.
The IPF platform's U.S. patents provide a legal framework, but enforcement requires resources. Competitors like Gilead and Merck have extensive patent estates that generate significant licensing revenue. NIKA's intellectual property has yet to be converted into consistent cash flow.
Valuation Context: Speculation Without Substance
At $0.38 per share, NIKA trades at a $398 million market capitalization and $398 million enterprise value. This valuation is not based on current revenue or earnings. With zero revenue and negative book value, traditional multiples like price-to-earnings or price-to-book are not applicable.
Comparing NIKA to established pharmaceutical companies highlights the valuation gap. Gilead trades at 5.89x sales, Merck trades at 4.60x sales, and Pfizer trades at 2.57x sales. NIKA's valuation is based on future expectations of revenue generation despite having no currently approved products or active manufacturing capacity.
The primary valuation metric is cash runway relative to burn rate. With $79,654 in annual cash burn and minimal cash on hand, NIKA relies on continued insider funding. The $398 million valuation assumes the Bulgarian factory will generate significant revenue in the near term, a timeline that faces various logistical and regulatory requirements.
Return on assets of -245.31% indicates that the company is currently losing more than its total asset value annually. The beta of 0.12 suggests low correlation with the broader market, which is often a characteristic of illiquid stocks with low institutional ownership.
Conclusion: The Binary Outcome of a Broken Business Model
NIKA Pharmaceuticals represents a speculation on the willingness of CEO Dimitar Savov to continue funding the entity. The $398 million market capitalization reflects a bet that the Bulgarian factory will create value despite NIKA's current lack of regulatory approvals or established manufacturing.
The outcome appears binary: either NIKA secures significant external financing to conduct modern clinical trials and commercialize its products, or the company exhausts its current funding sources. There is little evidence of a middle path where modest success justifies the current valuation.
The critical variables to monitor are financial: whether CEO Savov continues advancing funds, whether the Bulgarian factory becomes operational under NIKA's control, and whether the company can address its governance challenges to attract partnership interest. The central question for speculators is whether the company can reach operational milestones before its current financing model reaches its limit.
